drugset / Trial / NCT06912074

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

NCT06912074

Phase 2 Recruiting 134 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy following induction chemoimmunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Timeline

Start
2025-04-05
Primary completion
2029-04-04
Completion
2029-04-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Cisplatin Other / unclassified
Background Paclitaxel Small molecule
Background Toripalimab Monoclonal antibody